reports
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to l...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) ...
CapStar Financial Holdings, Inc. Announces Quarterly Dividend of $0.11...
CapStar Financial Holdings, Inc. Announces Quarterly Dividend of $0.11 per Share NASHVILLE, Tenn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ: CSTR) announced that on January 26, 2024, the Board of Directors of the Company approved a quarterly dividend of $0.11 per common share payable on February 21, 2024 to shareholders of record of CapStar’s common stock as of the close of business on February 7, 2024. About CapStar Financial Holdings, Inc. CapStar Financial Holdings, Inc. is a bank holding company headquartered in Nashville, Tennessee and o...
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operati...
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) K...
- Dave Nicoski
- Ross LaDuke
WABC WESTAMERICA BANCORPORATION
RGR STURM RUGER & COMPANY INC.
PPC PILGRIM'S PRIDE CORPORATION
MCY MERCURY GENERAL CORPORATION
LDOS LEIDOS HOLDINGS INC.
IBCP INDEPENDENT BANK CORP. MICHIGAN
HMN HORACE MANN EDUCATORS CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
GILD GILEAD SCIENCES INC.
EAT BRINKER INTERNATIONAL INC.
CUBI CUSTOMERS BANCORP INC.
CRK COMSTOCK RESOURCES INC.
CL COLGATE-PALMOLIVE COMPANY
BPMC BLUEPRINT MEDICINES CORP.
AR ANTERO RESOURCES CORPORATION
SAFT SAFETY INSURANCE GROUP INC.
AROW ARROW FINANCIAL CORP.
CHE CHEMED CORPORATION
NOC NORTHROP GRUMMAN CORPORATION
LMT LOCKHEED MARTIN CORPORATION
THG HANOVER INSURANCE GROUP INC.
WRB W. R. BERKLEY CORPORATION
ACNB ACNB CORP.
SRCE 1ST SOURCE CORP.
CSTR CAPSTAR FINANCIAL HOLDINGS
BL BEST LEASE
WRK WESTROCK COMPANY
NKE NIKE INC. CLASS B
ESSA ESSA BANCORP
CHMG CHEMUNG FINANCIAL CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ALXO ALX ONCOLOGY HOLDINGS
MODV MODIVCARE INC
VSCO VICTORIA'S SECRET & CO
CHK CHESAPEAKE ENERGY CORP
FRST PRIMIS FINANCIAL CORP
P RAILPOWER TECHNOLOGIES CORP.
MSBI HAMASHBIR 365 LTD
CapStar Reports Third Quarter 2023 Results
CapStar Reports Third Quarter 2023 Results NASHVILLE, Tenn., Oct. 26, 2023 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ:CSTR) today reported net income of $8.9 million or $0.43 per diluted share, for the quarter ended September 30, 2023, compared with net income of $7.8 million or $0.37 per diluted share, for the quarter ended June 30, 2023, and net income of $8.0 million or $0.37 per diluted share, for the quarter ended September 30, 2022. Annualized return on average assets and return on average equity for the quarter ended September 30, 2023 was 1.10% and 10...
- Dave Nicoski
- Ross LaDuke
TLYS TILLYS
SWN SOUTHWESTERN ENERGY COMPANY
SMLR SEMLER SCIENTIFC
NVEE NV5 GLOBAL INC.
MCY MERCURY GENERAL CORPORATION
HIBB HIBBETT SPORTS INC.
GPS GAP INC.
CVX CHEVRON CORPORATION
CRK COMSTOCK RESOURCES INC.
CMTL COMTECH TELECOMMUNICATIONS CORP.
CF CF INDUSTRIES HOLDINGS INC.
CDE COEUR MINING INC.
BKE BUCKLE INC.
AR ANTERO RESOURCES CORPORATION
AMSF AMERISAFE INC.
PRU PRUDENTIAL FINANCIAL INC.
SAFT SAFETY INSURANCE GROUP INC.
CNA CNA FINANCIAL CORPORATION
MLHR HERMAN MILLER INC.
MOV MOVADO GROUP INC.
PRA PROASSURANCE CORPORATION
WRB W. R. BERKLEY CORPORATION
UTHR UNITED THERAPEUTICS CORPORATION
CSTR CAPSTAR FINANCIAL HOLDINGS
SD SANDRIDGE ENERGY INC.
CMCL CALEDONIA MINING CORPORATION
NKE NIKE INC. CLASS B
ASGN ASGN INC
CDAY CERIDIAN HCM HOLDING INC.
MEC MAYVILLE ENGINEERING
NFE NEW FORTRESS ENERGY
KTB KONTOOR BRANDS
POWW AMMO INC
MODV MODIVCARE INC
HMN ASCOTT RESIDENCE TRUST
CHK CHESAPEAKE ENERGY CORP
FTREV FORTREA HOLDINGS INC.
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsens...
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three patients as improvement of kidney morphology is consistent with reduction or stabilization of proteinuria during or up to 2 months post co...
CapStar Announces Date for Third Quarter 2023 Earnings Release and Con...
CapStar Announces Date for Third Quarter 2023 Earnings Release and Conference Call NASHVILLE, Tenn., Oct. 04, 2023 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ: CSTR) announced today that it will issue its third quarter 2023 earnings release after the market closes on October 26, 2023. CapStar will also host a conference call and webcast at 10:00 a.m. Central Time on Friday, October 27, 2023 to discuss its financial results. Analysts and investors may participate in the question-and-answer session. Conference Call and Webcast Information: Date: Friday,...
CapStar Names Bryan Fryar Chattanooga Market President
CapStar Names Bryan Fryar Chattanooga Market President Announces the Addition of Two Commercial Relationship Managers NASHVILLE, Tenn., Sept. 22, 2023 (GLOBE NEWSWIRE) -- CapStar Bank, a subsidiary of CapStar Financial Holdings (NASDAQ: CSTR), announces the promotion of Bryan Fryar to Chattanooga Market President and the addition of two local commercial bankers to the Chattanooga banking group, forming one of the region’s strongest banking teams. The Bank currently has one full-service location on the ground floor of the historic James Building at 735 Broad Street to serve the Chattano...
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering ...
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced...
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Bio...
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport...
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013 Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration Significant strategic interest in ZKN-01...
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operat...
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02 Announced achievement of remission in one patient in Phase 2 clinical study of ELX-02 for the treatment of Alport syndrome and decision to advance ELX-02 into a pivotal trial in Alport syndrome Highlighted significant unmet need in the t...
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated wi...
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport syndrome Together with previously announced rapid and sustained proteinuria remission in one patient in Phase 2 clinical study, these biopsy results strongly support decision ...
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance...
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.